| Total | Cedar Pollinosis (-) | Cedar Pollinosis (+) |
---|---|---|---|
No. patients | 333 | 217 | 116 |
Age, yr | 48.3 ± 1.0 | 48.7 ± 1.3 | 47.5 ± 1.6 |
Sex, n (%) | Â | Â | Â |
   Male | 137 (41.1) | 91 (41.9) | 46 (39.7) |
   Female | 196 (58.9) | 126 (58.1) | 70 (60.3) |
Type Atopic, n (%) | 211 (63.4) | 129 (59.5) | 82 (70.7) |
   Nonatopic | 122 (36.6) | 88 (40.5) | 34 (29.3) |
Duration of asthma, yr | 15.3 ± 0.8 | 15.0 ± 1.0 | 15.8 ± 1.3 |
IgE RIST (U/mL) | 565.8 ± 51.6 | 580.6 ± 72.9 | 538.9 ± 60.3 |
Cedar RAST (UA/mL) | 10.9 ± 1.4 | 4.2 ± 1.2 | 23.4 ± 2.8 |
Histamine-PC20 (μg/mL) | 1424 ± 194 (n = 125) | 1550 ± 262 (n = 81) | 1193 ± 267 (n = 44) |
Severity of asthma, n (%) | Â | Â | Â |
   Mild | 81 (24.3) | 54 (24.9) | 27 (23.3) |
   Moderate | 177 (53.2) | 116 (53.5) | 61 (52.6) |
   Severe | 75 (22.5) | 47 (21.6) | 28 (24.1) |
Therapy, n (%) | Â | Â | Â |
   BDP | 275 (82.6) | 182 (83.9) | 93 (80.2) |
   Slow-release theophylline | 259 (77.8) | 165 (76.0) | 94 (81.0) |
   Oral β2-agonists | 126 (37.8) | 77 (35.5) | 49 (42.2) |
Anti-allergic agents, n (%) | 57 (17.1) | 37 (17.1) | 20 (17.2) |
Oral steroids, n (%) | 20 (6.0) | 13 (6.0) | 7 (6.0) |